[1]刘颖,李争,张玉焕,等.芪参益气汤联合厄贝沙坦治疗老年慢性心力衰竭临床观察[J].西部中医药,2020,33(06):98-101.[doi:10.12174/j.issn.1004-6852.2020.06.26]
 LIU Ying,LI Zheng,ZHANG Yuhuan,et al.Clinical observation on Qishen Yiqi Tang and Irbesartan in Treating Senile Patients with Chronic Heart Failure[J].Western Journal of Traditional Chinese Medicine,2020,33(06):98-101.[doi:10.12174/j.issn.1004-6852.2020.06.26]
点击复制

芪参益气汤联合厄贝沙坦治疗老年慢性心力衰竭临床观察
分享到:

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
33
期数:
2020年06期
页码:
98-101
栏目:
报道·衷中参西
出版日期:
2020-06-15

文章信息/Info

Title:
Clinical observation on Qishen Yiqi Tang and Irbesartan in Treating Senile Patients with Chronic Heart Failure
文章编号:
1004-6852(2020)06-0098-04
作者:
刘颖李争张玉焕刘薇李凤娥宋郁珍
唐山市中医院,河北 唐山 063000
Author(s):
LIU Ying LI Zheng ZHANG Yuhuan LIU Wei LI Feng′e SONG Yuzhen
Tangshan City TCM Hospital, Tangshan 063000, China
关键词:
芪参益气汤厄贝沙坦老年慢性心力衰竭炎症因子心功能
Keywords:
Qishen Yiqi Tang irbesartan the elderly chronic heart failure inflammatory factorscardiac function
分类号:
R541.6+1
DOI:
10.12174/j.issn.1004-6852.2020.06.26
文献标志码:
B
摘要:
目的:探讨芪参益气汤联合厄贝沙坦对老年慢性心力衰竭患者血清炎症因子及心功能的影响。方法:将94例患者随机分为两组,每组47例。对照组采用厄贝沙坦口服,0.15 g/次。每日1次;观察组在此基础上服用芪参益气汤,2组均于治疗8周后进行疗效评价。比较两组临床疗效、外周血肿瘤坏死因子α(tumor necrosis factor-α,TNF-α)、白细胞介素6(Interleukin-6,IL-6)及左心室收缩末期内径(Left ventricular end systolic diameter,LVESD)、左心室舒张末期内径(left ventricular end diastolic diameter,LVEDD)、左心射血分数(left ventricular ejection fraction,LVEF),记录不良反应。结果:总有效率对照组为78.72%(37/47),观察组为93.62%(44/47),差异有统计学意义(P<0.05)。治疗后对照组和观察组血清TNF-α分别为(143.49±21.67)μg/L、(127.24±20.19)μg/L,血清IL-6分别为(167.21±37.64)ng/L、(135.94±34.25)ng/L,LVESD分别为(46.40±4.97)cm、(42.11±4.25)cm,LVEDD分别为(56.54±4.13)cm、(53.10±3.89)cm,LVEF分别为(42.01±4.19)%、(47.52±5.36)%,上述指标两组比较,差异有统计学意义(P<0.05)。不良反应发生率对照组为12.77%(6/47),观察组为17.02%(8/47),两组比较差异无统计学意义(P>0.05)。结论:芪参益气汤联合厄贝沙坦治疗老年慢性心力衰竭患者疗效显著,可以降低血清炎症因子水平,改善心功能,且安全性较高。
Abstract:
Objective: To explore the effects of Qishen Yiqi Tang and irbesartan on serum inflammatory factors and cardiac function of senile patients with chronic heart failure (CHF). Methods: All 94 patients were randomized into two groups, 47 cases each group. The control group took irbesartan orally, 0.15 g each time, once each day, the observation group took Qishen Yiqi Tang, to assess clinical effects after treating eight weeks consecutively. To survey clinical effects, TNF-α, IL-6, LVESD, LVEDD and LVEF between both groups, to record adverse reaction. Results: Total effective rate of the control group was 78.72% (37/47), lower than 93.62% (44/47) of the observation group, and the difference had statistical meaning (P<0.05). After treating, the concentrations of TNF-α in the control group and the observation group were (143.49±21.67)μg/L and (127.24±20.19)μg/L respectively, the contents of IL-6 (167.21±37.64)ng/L and (135.94±34.25)ng/L, LVESD (46.40±4.97)cm and (42.11±4.25)cm, LVEDD (56.54±4.13)cm and (53.10±3.89)cm, and LVEF (42.01±4.19)% and (47.52±5.36)%, the difference was statistically significant in the comparisons of these indexes between both groups (P<0.05). The incidence of adverse reaction of the control group was 12.77% (6/47), lower than 17.02% (8/47) of the observation group, and the difference had no statistical meaning between both groups (P>0.05). Conclusion: Qishen Yiqi Tang and irbesartan are effective in treating CHF in the elderly, lower inflammatory factors, improve cardiac function with higher safety.

相似文献/References:

[1]林晓芬,黄燕璇.益肾汤联合厄贝沙坦及胰激肽原酶治疗早期糖尿病肾病的疗效观察[J].西部中医药,2013,26(07):68.
 LIN Xiaofen,HUANG Yanxuan.Clinical Observation on YiShenTang Combined with Irbesartan and Pancreatic Kininogenase in the Treatment for Early Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(06):68.
[2]马咏梅.厄贝沙坦与黄葵胶囊对糖尿病肾病患者血清胱抑素C和β2-微球蛋白的影响[J].西部中医药,2017,30(11):106.
 MA Yongmei.Effects of Irbesartan and Ambrette Capsules on Serum Cystatin C and β2-microgloblin of the Patients with Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2017,30(06):106.

备注/Memo

备注/Memo:
收稿日期:2019-08-24*基金项目:河北省中医药管理局科研计划项目(2018319)。作者简介:刘颖(1978—),女,主治医师。研究方向:心力衰竭的临床诊治。
更新日期/Last Update: 2020-06-15